

FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval for generic Astelin[®] Nasal Spray

Mumbai, May 24, 2012: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for its generic version of Astelin[®], Azelastine HCL Nasal Spray, 0.1% (137 mcg/spray).

This generic Azelastine HCL Nasal Spray, 0.1% (137 mcg/spray) is therapeutically equivalent to Astelin[®] Nasal Spray from Medpointe Pharm HLC. Azelastine HCL nasal spray has annual sales of approximately \$ 144 million in the US.

Azelastine HCL Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing and nasal pruritus; and the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older.

Astelin[®] is a registered trademark of Medpointe Pharm HLC (Medpointe)

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, gastroenterology, ophthalmology and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota		Mira Desai	
Tel	+91 22 6645 5645, Xtn 605	Tel	+91 22 6645 5645, Xtn 606
Tel Direct	+91 22 66455605	Tel Direct	+91 22 66455606
Mobile	+91 98670 10529	Mobile	+91 98219 23797
E mail	uday.baldota@sunpharma.com	E mail	mira.desai@sunpharma.com